Holdings
Bellevue Group AG
As of Jun 30, 2026, Bellevue Group AG reported 133 positions worth US$4.53B. Largest: Amgen Inc., Vertex Pharmaceuticals Incorporated and Argenx Se. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Amgen Inc. | 852K | US$308M | +556K | Jun 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 579K | US$287M | −103K | Jun 30, 2026 |
| Argenx Se | 301K | US$279M | −12,000 | Jun 30, 2026 |
| Gilead Sciences, Inc. | 2.16M | US$273M | +989K | Jun 30, 2026 |
| Revolution Medicines, Inc. | 1.05M | US$196M | −496K | Jun 30, 2026 |
| Oruka Therapeutics, Inc. | 1.66M | US$158M | +1.15M | Jun 30, 2026 |
| Insmed Incorporated | 1.39M | US$149M | +1.38M | Jun 30, 2026 |
| Scholar Rock Holding Corporation | 2.45M | US$135M | −1.14M | Jun 30, 2026 |
| Nuvalent, Inc. | 1.05M | US$130M | no change | Jun 30, 2026 |
| Viridian Therapeutics, Inc. | 6.73M | US$124M | +5,765 | Jun 30, 2026 |